||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Glaxosmithkline Share Discussion Threads
Showing 19251 to 19274 of 19275 messages
|Plenty of time to get it.|
|Did not get to my add price today, hopefully an opportunity tomorrow.
Presidential debate later.|
|Minerve,Losos good posts agree with your points.|
|It is partly tied up as well with the fact that holding an investment gives little return because of the near zero interest rates versus the capital gain on a business sale or restructuring.|
|Minerve - "I think the issue is a general problem for all capitalism at the moment."
Yes, something must be done to curtail this ever increasing 'short term' attitude which as you say is basicly driven by what I can only term 'greed'
Hedge funds and private equity groups should not determine the long term outlook for a company. The current discussion on GSK is very typical. Break it up, make lots of dosh, sell the individual parts on, repeat the whole process with some other big company.
While all that is going on the people in the R&D departments don't know what the company status will be in 10 or 20 years so can hardly be blamed for not looking for genuine new discoveries.|
|Also, statistics show that in Germany, women occupy only 8.7 percent of the management positions in companies with more than 500 employees. In fact, in 2012, women accounted for a mere 4 percent of management positions in 100 – 200 of Germany’s largest companies. According to a study conducted in 2012 by Mercer Deutschland GmbH, a management consulting firm, Germany just about manages to be ranked 28 out of 29 European countries in this regard.|
Unfortunately that is the problem with many companies in the uk,the city is too short termism when it comes to investing in companies,Germany has the right idea they have a much longer horizon with investing.|
|There will always be this friction. Big Pharma is, by definition, a very long term business as it researches and brings drugs to market. The short term investors are more interested in breaking up the business and making a quick buck.|
|GlaxoSmithKline faces mounting investor anger over the promotion of the drugmaker’s consumer healthcare boss to the top job.
Some big shareholders in the FTSE 100 giant are understood to be unhappy with the decision to appoint Emma Walmsley to succeed Sir Andrew Witty as chief executive.
Her rise to the helm of the sixth-biggest company in the FTSE 100 has been hailed as a milestone in the push to increase the representation of women in boardrooms. As head of the £80bn pharmaceuticals giant, Ms Walmsley will be one of the most influential figures in British business.
However, some investors would have rather seen an external candidate appointed, and believe the promotion signals Ms Walmsley is unlikely to deviate from the strategy laid out by Sir Andrew.He had resisted investor pressure to bolster sales and profits by spinning off parts of the company.|
|LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it has filed a U.S. regulatory submission for sirukumab in rheumatoid arthritis.
The pharmaceutical giant has submitted a biologics license application to the U.S. Food and Drug Administration by Janssen Biotech, Inc., seeking approval of a subcutaneous formulation of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have failed, or are intolerant to one or more disease-modifying antirheumatic drugs.
Sirukumab is being co-developed for rheumatoid arthritis as part of a collaboration with Janssen Biologics (Ireland), an affiliate of JBI.
A regulatory submission to the European Medicines Agency was announced on Sept. 12. Sirukumab is currently not approved as a treatment for any indication anywhere in the world.|
|Pocket money to you EI :)|
|CNBC highlighted a case of price gouging yesterday, an extraordinary situation
of an anti acne creme being sold for $ thousands, thousands for one tube of cream.|
|Quite a good rise in the US last night, hopefully positive opening this morning|
N.B. Probably worth holding just as an anti-dote to the constantly falling UKPound.|
|Emma is with GSK since 2010 and is heading GSK consumer healthcare since 2012... Before she was for 17 years with l'Oriel, cosmetics which is another regulated industry. With her modern languages degrees, she is an excellent international communicator. It's the great communicators with high emotional intelligence that make the best leaders. She is MORE than qualified or experienced to head GSK. Read up...|
|Nice intra-day reversal for GSK stateside.
Added a few more before the close.|
|In addition to Hilary.....|
Some of the re-ratings are really just adjustments on pound devaluation. My issue on this stock and AZN is flat dividend growth and waiting conformation that the patent cliff has been vaulted on both. I have Roche & Abbvie because prospects on both at the very least look better on dividend growth and are slightly more affordable for the companies because of lower yields.|
|M, problem I'm finding in terms of share additions is
some of the huge recent re-ratings.
Added a small amount, hoped for a second lot today lower
but not happened so far.|
|Witty was probably the last of the pure Glaxo breed. I don't know whether the China affair was ex SK or Glaxo or started under GSK.
I believe that Witty did stabilise the group.|
|Not currently holding here. Wait and see if a second wave of the Hilary effect hits sentiment if she beats the mega-fit buffoon (😂) to the presidency.|
|TraderMichael20 Sep '16 - 08:34 - 13172 of 13198
" A degree in Modern Languages and Classics .... a career in cosmetics ...... just what you need to head up a world-leading pharmaceuticals, vaccines and healthcare company. "
Nothing wrong with that at all. Leading pharmaceutical companies are looking for talent outside of normal avenues. I know this for a fact having visited many top universities recently. Warwick University has actually started a new liberal arts degree to attract humanities students etc.. in part due to request from pharmas and other blue chips looking for someone different who can think different. Medical students all think the same way and talk the same way, and of course they would do, they have all had identical training. Many classical students are extremely clever and end-up as some of our best talent in GCHQ etc..
Vocational learning is so dated and only applies to certain niches nowadays.|
|Andrew was effectively shown the door,
and he is replaced by the head of CH, oh my.
AW read how the pharma industry was going to develop like a book,
he has been validated.
My own take is the last China scandal was probably his undoing,
he will be a very big loss to GSK,
appreciate others may see it differently.|